Floatz Rating
B63/100
Confidence
Indicative
Sponsor
First Affiliated Hospital Xi'an Jiaotong University
Modality
protein_peptide
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05551247CT.gov Envafolimab Combined With Endostatin in Recurrent or Metastatic MSS-type Colorectal Cancer | — | Unknown | — | — | — |
NCT02748772CT.gov Application of Two Anti-angiogenesis Drugs Combined With Chemotherapy in Advanced Colorectal Cancer Under the Background of Precision Medical | — | Unknown | — | — | — |
NCT00813137CT.gov FOLFOX4 Combined With Endostar in Patients With Advanced Colorectal Cancer | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Colorectal Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Endostatin (this asset) | First Affiliated Hospital Xi'an Jiaotong University | P3 | B · 63 |
| Oxaliplatin | Peking University Cancer Hospital & Institute | P4 | BBB |
| Fluorouracilum | Rutgers, The State University of New Jersey | P4 | BBB |
| Irinotecan | Shanghai Zhongshan Hospital | P4 | BBB |
| Ferric Carboxymaltose [Ferinject] | Nottingham University Hospitals NHS Trust | P4 | BBB |
| Regorafenib | Sergey Orlov, MD | P4 | BB |
| Capecitabine | Rutgers, The State University of New Jersey | P4 | BB |
| Nivolumab | Bristol-Myers Squibb | P3 | BB |
| Barii Sulfas | London North West Healthcare NHS Trust | P4 | BB |
+41 more in the Colorectal Neoplasm cohort
Other indications for Endostatin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P4 | BB · 70 |
| Lung Cancer | — | P4 | B · 60 |
| Lung Neoplasm | — | P3 | B · 59 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Endostatin in Colorectal Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/endostatin-colorectal-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →